# AdhereR: Estimate Adherence from Electronic Healthcare Data

Samuel S. Allemann, Alexandra L. Dima 21 November 2019

## Why EHD?

- · data available from routine care for large samples with minimal extra costs
  - Estimate prevalence of (non-)adherence
  - Identify predictors of (non-)adherence
  - Model impact of adherence on clinical outcomes
  - Identify individuals with suboptimal adherence for targeted interventions
- limitations:
  - low granularity
  - variable data entry quality & standards
  - limited info recorded

## Typically available information

- Patient identifier
- · Date of event
- Type of medication
- Quantity prescribed/dispensed/billed

## Methodology matters

- · Different adherence estimates from the same data
- Insufficiently reported algorithms
- Lack of standardization and transparency
- · Misinformed clinical decisions

## Example: Method-related variation in adherence to sibutramine

Measure	Formula	Value	Result (Standard Deviation)
CMA <sup>17</sup>	cumulative days' supply of medication obtained/total days to next fill or to end of observation period	adherence value for cumulative time period	0.635 (0.29)
CMG <sup>17</sup>	total days of treatment gaps/total days to next fill or end of observation period	nonadherence value for cumulative period, winsorized at zero	0.370 (0.28)
CMOS <sup>13</sup>	total days of treatment gaps (+) or surplus <sup>a</sup> (–)/total days in observation period	nonadherence value for cumulative period, allowing for surplus	0.365 (0.29)
CR <sup>24</sup>	(total days supplied – last days' supply)/(last claim date – first claim date) $\times$ 100	adherence value for period between fills	84.4% (0.22) <sup>b</sup>
CSA <sup>17</sup>	days' supply obtained at beginning of interval/days in interval	adherence value for interval of study participation	1.097 (1.73)
DBR <sup>22</sup>	1 – {[(last claim date – first claim date) – total days' supply]/ (last claim date – first claim date)} $\times$ 100	overall adherence percentage	104.8% (38.6)
MPR <sup>16</sup>	days' supply: days in period	ratio of medication available	0.635:1 (0.29)
MPRm <sup>26</sup>	[total days supplied/(last claim date – first claim date + last days' supply)] $\times$ 100	adherence percentage, adjusted to include final refill period	86.6% (16.6)
MRA <sup>23</sup>	(total days' supply/total number of days evaluated) × 100	overall adherence percentage	63.5% (29.1)
PDC <sup>27</sup>	(total days supply/total number of days evaluated) $\times100\%,$ capped at $1.0^a$	percentage of days with medication available	63.0% (28.3)
RCR <sup>25</sup>	[(sum of quantity dispensed over interval/quantity to be taken per day) $\times$ 100]/number of days in interval between first and last refill	overall adherence percentage	104.8% (38.6)

LM Hess - 2006. <a href="https://doi.org/10.1345/aph.1H018">https://doi.org/10.1345/aph.1H018</a> (https://doi.org/10.1345/aph.1H018).

### **AdhereR**

- Open-source package for the statistical software R
- Computation of adherence from EHD
- · (Interactive) visualization
- Transparent and reproducible reporting
- · Under active development

## Assumptions

- The regimen requires the use of a fixed daily dosage of medication
- · All medication supplied for that patient in that period of time is recorded
- The patient does not use medication from other sources
- · The medication is used by the patient it has been supplied for
- Medication is supposed to be supplied at least two times during the observed period
- · Several other assumptions apply to individual algorithms


### **Definitions: Data source**

- Medication event = prescribing or dispensing event of a given medication for a given patient
- Duration = number of days the quantity of supplied medication would last if used as recommended
- *Quantity* = number of doses supplied at a medication event
- Daily dosage = number of doses recommended to be taken daily
- Medication type = classification performed by the researcher depending on study aims

## Definitions: Adherence taxonomy


- Adherence
  - continuous multiple-interval measures of medication availability (CMA)
- Initiation
  - the length of time between the first prescribing event and the first dispensing event
- Persistence
  - the length of time with repeated medication events, before discontinuing for a time period longer than a pre-specified permissible gap
- Implementation
  - CMA during treatment episodes or observation windows with no treatment gaps longer than a pre-specified period

## **ABC Taxonomy for EHD**



### **Definitions: Time frames**

- Follow-up window (FUW)
- Observation window (OW)
- Treatment episode (TE)




## Working with AdhereR

- 1. Data preparation
- 2. Data exploration / Visualization
- 3. Adherence calculation
- 4. Reporting

## **Prerequisites**

- The raw data (A),
- · A tidy data set (B),
- · A code book with all variables and values in the tidy data set,
- · A reproducible recipe how to go from A to B.

## Why reproducibility is important



Herndon, T., Ash, M., & Pollin, R. (2014). Cambridge journal of economics, 38(2), 257-279.


### 1. Data preparation

- selecting medication events applicable to the research question
- coding medication type depending on clinical considerations
- calculate medication event durations (if necessary)
- check plausible values and correcting any deviations
- handle missing data
- see Huang, Yunyu, Jaco Voorham, und Flora M Haaijer-Ruskamp. Journal of Comparative Effectiveness Research 5, Nr. 4 (27. Juni 2016): 345-54. https://doi.org/10.2217/cer-2015-0022 (https://doi.org/10.2217/cer-2015-0022).


## 2. Data exploration/Visualization


- Exploration during preparation stage
- · Illustration for scientific communication
- Guidance in clinical practice

#### Event patterns (all patients aligned)



## **Interactive Plotting**





### 3. Adherence calculations

- AdhereR estimates adherence as Continuous Medication Availability (CMA)
- simple CMA measures: CMA1 CMA9
  - Delimitation of OW,
  - Capping of CMA values,
  - Carry-over of medication oversupply within the OW, and
  - Carry-over of medication supply into OW.
- iterated CMA measures: CMA\_per\_episode and CMA\_sliding\_window

## Overall adherence - implementation & persistence

- · CMA itself makes no difference between persistence/non-persistence
- CMA = implementation only if sample/individual is on treatment
  - *simple* CMA for sample that initiated and did not discontinue OR
  - per episode CMA first identifies treatment episodes then computes CMA for each

### Overall adherence with CMA7

### **Initiation**


- Requires prescription and dispensing data for the same follow-up period
- yes/no availability of a dispensing date (within a period of time after prescription)
- time to dispensing time to initiation() function


### Time to initiation

```
time_to_initiation(disp.data, presc.data, ...)
## Warning in time_to_initiation(presc.data = prescription_episodes[grepl("^R03AC", : Dis
```

### Persistence

· differentiate between persistence with treatment and quality of implementation






### Persistence

compute.treatment.episodes(data, ...)



#### Event patterns (all patients aligned)



## Persistence output

ID	episode.ID	episode.start	end.episode.gap.days	episode.duration	episode.end
7	1	2056-07-07	169	30	2056-08-06
7	2	2057-01-22	145	93	2057-04-25
7	3	2057-09-17	118	30	2057-10-17
7	4	2058-02-12	405	105	2058-05-28
16	1	2056-07-04	0	517	2057-12-03
16	2	2057-12-03	158	420	2059-01-27

## **Implementation**

- · CMA per episode
- CMA\_per\_episode(CMA, data, ...)



Error: undefined columns selected

## Longitudinal analysis

- for time-series, (e.g., GEE), or group-based trajectory models
- CMA\_sliding\_window(CMA.to.apply="CMA9", data, ...)



Error: arguments imply differing number of rows: 1, 8

## Dealing with Polypharmacy

- calculation of one single adherence value: Continuous Aggregated Polypharmacy Score (CAPS)
- Process with 4 components:
  - Grouping of related medication classes into treatment groups
  - Prepare data (adjust observation window, apply carryover, cover special periods, etc.)
  - Aggregate across treatment groups
  - Summarize over time

## Treatment groups

- treatment-switches vs. two-drug regimens
- decide which medications can be used interchangeably
- e.g. based on ATC codes

((example visualization))

## Aggregation methods

- Periods with ANY treatment available
- Periods with ALL treatments available
- Average of CMAs for individual treatments
- Average of all treatments available per intervall
- Dichotomized: CMA for individual treatments larger than cutoff

((Examples))

## Function CMA\_polypharmacy

((show function & example))

## 4. Reporting

- · describe data preparation choices
- justify choice of functions
- report any sensitivity analyses
- share the analysis code (and anonymized dataset, if possible)
- · use RMarkdown to embed code and R plots in your reports

## Take home messages

- Data Preparation & Exploration are essential for meaningful estimation of adherence
- Meaningful Adherence estimation requires clear operationalization of the reported measure
- AdhereR provides functions to prepare, analyze, and visualize EHD
- · AdhereR functions are flexible, transparent, and ensure reproducibility

## Practical session(s)

- interactive online-tutorial with example data (for beginners)
- commented R script to use within R Studio (for advanced R users)
- · R-Markdown document with explanations and code examples for reference